Appistry Extends Solutions for Next-Generation Sequencing Data Analysis

Firstly the upcoming release of GenomePilot™ 4.0 will incorporate the capability to perform differential expression analysis of RNA-Seq data.

“Many of our customers are faced with the challenge of migrating traditional gene expression arrays to next-generation sequencing using RNA-Seq data,” said Dr. Trevor Heritage, chief strategy officer for Appistry. “Building and executing a RNA-Seq analysis pipeline requires extensive knowledge in bioinformatics, scripting and multivariate analysis which poses a challenge for many labs. Customers have found value in the accessibility, reproducibility and scalability we have brought to analyzing DNA data with GenomePilot. The extension of those same attributes to RNA data saves our customers a considerable amount of time and resources.”

GenomePilot 4.0 focuses on providing an easier way for customers to analyze RNA-Seq data by enabling differential expression analysis in three easy steps:

1. Feature Counts – With a few clicks the user can define a feature count pipeline to identify gene counts for analysis.
2. Experiment Builder – The innovative and intuitive Experiment Builder enables users to easily create an experiment with traits to be analyzed, while GenomePilot auto-populates gene counts into the workflow.
3. Differential Expression – Users can quickly run differential expression analyses and visualize their results within one system without programming or working in multiple tools.

Live demonstrations of GenomePilot 4.0 will be held in Appistry booth #40 at the upcoming Next Generation Dx Summit in Washington D.C. August 23-26 with customer availability on September 15, 2016.

Secondly, Appistry will begin previewing a new product to the market, GenomeNavigator™, which will focus on variant prioritization, clinical interpretation and reporting.

“At Appistry we focus on building innovative, intuitive solutions that enable a more efficient and accessible process for the identification, qualification, and interpretation of variants for clinical application,” said Kevin Haar CEO of Appistry. “The launch of GenomePilot last year addressed the first part of the analysis workflow by delivering a simpler way for labs to identify and qualify variants of interest. GenomeNavigator will address the second part of the workflow with an interactive and innovative approach to prioritize and interpret variants for clinical application. We are offering early previews of GenomeNavigator with the goal of gathering customer insight and feedback into the development process before release later this year.”

Previews of GenomeNavigator for interested parties can be requested by visiting Appistry.com/contact.

About Appistry:

Appistry is a scientific software company that bridges the gap between genomics data and health outcomes by making next-generation sequencing data analysis more approachable and actionable to improve clinical decisions. With roots in high-performance computing, big data, and life sciences we bring a unique level of expertise to helping our customers solve complex problems and transform data into actionable information.